The Claim
Intermittent administration of dasatinib plus quercetin in postmenopausal women over a 20-week period is associated with no serious adverse events, despite a high incidence of mild side effects including headache (53%) and gastrointestinal complaints.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In postmenopausal women taking intermittent doses of dasatinib and quercetin for 20 weeks, no serious side effects were reported, but many experienced mild side effects such as headaches and stomach issues.
See the scientific wording
Intermittent dasatinib plus quercetin is safe in postmenopausal women over 20 weeks, with no serious adverse events reported despite a high rate of mild side effects including headache (53%) and gastrointestinal complaints.
A combination of two drugs removes old, damaged cells in the body, which lowers a protein that blocks bone growth. This allows bone-building cells to work more actively, leading to stronger bones over time.
What the research says
1 studyThis study gave postmenopausal women a monthly combo of two drugs for 20 weeks and found they had lots of mild side effects like headaches and stomach issues, but no one had serious health problems — which matches the claim exactly.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.